Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Trial sponsor
Gritstone Oncology, Bristol-Myers Squibb (BMS)
Scientific Title
An International Phase 1/2 Study of GRT-C901/GRT-R902, a Neoantigen Cancer Vaccine, in Combination With Immune Checkpoint Blockade for Patients With Advanced Solid Tumors